An Analysis of Leukapheresis and Central Venous Catheter Use in the Randomized, Placebo Controlled, Phase 3 IMPACT Trial of Sipuleucel-T for Metastatic Castrate Resistant Prostate Cancer-Reference-Cited by-同舟云学术

An Analysis of Leukapheresis and Central Venous Catheter Use in the Randomized, Placebo Controlled, Phase 3 IMPACT Trial of Sipuleucel-T for Metastatic Castrate Resistant Prostate Cancer

Published:2013-02 Issue:2 Volume:189 Page:521-526
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Flanigan Robert C.¹,Polcari Anthony J.¹,Shore Neil D.²,Price Thomas H.³,Sims Robert B.⁴,Maher Johnathan C.⁴,Whitmore James B.⁴,Corman John M.⁵

Affiliation:

1. Loyola University Stritch School of Medicine, Maywood, Illinois

2. Atlantic Urology Clinics, Myrtle Beach, South Carolina

3. Puget Sound Blood Center, Seattle, Washington

4. Dendreon Corporation, Seattle, Washington

5. Virginia Mason Medical Center, Seattle, Washington

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference24 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

3. Expanding treatment options for metastatic prostate cancer;Antonarakis;N Engl J Med,2011

4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

5. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors;Bolan;Blood,2002

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Apheresis in Personalized Cell-Mediated Treatment of Prostate Cancer;Prostate Cancer;2024

2. Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines;Human Vaccines & Immunotherapeutics;2023-01-02

3. Vascular access in therapeutic apheresis: One size does not fit all;Therapeutic Apheresis and Dialysis;2022-02-06

4. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution;Cancer Immunotherapies;2022

5. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017;JAMA Network Open;2019-08-14